Cargando…

Pediatric visceral leishmaniasis in northwest of Iran

Leishmaniasis is one of the major health problems in Iran. Although the incidence of visceral leishmaniasis (VL) is reported almost everywhere, the northwestern Iran is one of the major endemic regions. To do this study, clinical, laboratory as well as disease characteristics of children admitted to...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdinia, Babak, Oliaei-Motlagh, Mohammad, Teimouri-Dereshki, Amir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591139/
https://www.ncbi.nlm.nih.gov/pubmed/27858891
http://dx.doi.org/10.1097/MD.0000000000005261
_version_ 1783262649690095616
author Abdinia, Babak
Oliaei-Motlagh, Mohammad
Teimouri-Dereshki, Amir
author_facet Abdinia, Babak
Oliaei-Motlagh, Mohammad
Teimouri-Dereshki, Amir
author_sort Abdinia, Babak
collection PubMed
description Leishmaniasis is one of the major health problems in Iran. Although the incidence of visceral leishmaniasis (VL) is reported almost everywhere, the northwestern Iran is one of the major endemic regions. To do this study, clinical, laboratory as well as disease characteristics of children admitted to Children Cure and Health Hospital, Tabriz University of Medical Sciences, were examined as the reference hospital for the treatment of VL in northwestern Iran. In this study, 156 children hospitalized in a pediatric hospital from 2000 to 2015 for VL were included. Gender, age, anemia, thrombocytopenia, increase in the erythrocyte sedimentation rate (ESR), alanine transaminase (SGPT), and aspartate transaminase (SGOT), major clinical manifestations such as fever, splenomegaly, hepatomegaly, treatment type, and the disease were studied. Among 156 patients examined in this study, 88 (56.41%) and 68 (43.59%) participants were male and female, respectively. The minimum and maximum ages of the infection were 4.5 months and 6 years, respectively. The mean age of the infected children was 17.94 months. Fever (94.24%) and splenomegaly (86.53%) were the most common symptoms of this disease among children. In addition, 49 (31.41%), 64 (41.02%), 18 (11.53%), 33 (21.15%), and 40 (25.64%) participants had leukopenia, hemoglobin count below 8, ESR above 100, ESR above 60, and platelets below 100,000, respectively. Moreover, 39 (25%) and 17 (10.89%) patients had high aspartate transaminase (AST) and alanine transaminase (ALT). Also, 96.2% of the participants responded to the treatment with glucantime. The rate of mortality in this study was 3.2%. Clinically, almost all children had fever and splenomegaly at the onset of the disease. In addition, hepatic involvement was observed in all cases of mortality, cases with a lack of initial response, and those in need of auxiliary medication. Hepatic involvement appears to be related to the prognosis of the disease. In our study, bone marrow aspiration (BMA) and positive direct antiglobulin test (DAT) were observed in 66.67% and more than 90% of the patients, respectively. Children with VL in northwestern Iran responded well to glucantime. In case of resistance, amphotericin B was a good alternative. Early diagnosis is essential in reducing mortality rate.
format Online
Article
Text
id pubmed-5591139
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-55911392017-09-15 Pediatric visceral leishmaniasis in northwest of Iran Abdinia, Babak Oliaei-Motlagh, Mohammad Teimouri-Dereshki, Amir Medicine (Baltimore) 4900 Leishmaniasis is one of the major health problems in Iran. Although the incidence of visceral leishmaniasis (VL) is reported almost everywhere, the northwestern Iran is one of the major endemic regions. To do this study, clinical, laboratory as well as disease characteristics of children admitted to Children Cure and Health Hospital, Tabriz University of Medical Sciences, were examined as the reference hospital for the treatment of VL in northwestern Iran. In this study, 156 children hospitalized in a pediatric hospital from 2000 to 2015 for VL were included. Gender, age, anemia, thrombocytopenia, increase in the erythrocyte sedimentation rate (ESR), alanine transaminase (SGPT), and aspartate transaminase (SGOT), major clinical manifestations such as fever, splenomegaly, hepatomegaly, treatment type, and the disease were studied. Among 156 patients examined in this study, 88 (56.41%) and 68 (43.59%) participants were male and female, respectively. The minimum and maximum ages of the infection were 4.5 months and 6 years, respectively. The mean age of the infected children was 17.94 months. Fever (94.24%) and splenomegaly (86.53%) were the most common symptoms of this disease among children. In addition, 49 (31.41%), 64 (41.02%), 18 (11.53%), 33 (21.15%), and 40 (25.64%) participants had leukopenia, hemoglobin count below 8, ESR above 100, ESR above 60, and platelets below 100,000, respectively. Moreover, 39 (25%) and 17 (10.89%) patients had high aspartate transaminase (AST) and alanine transaminase (ALT). Also, 96.2% of the participants responded to the treatment with glucantime. The rate of mortality in this study was 3.2%. Clinically, almost all children had fever and splenomegaly at the onset of the disease. In addition, hepatic involvement was observed in all cases of mortality, cases with a lack of initial response, and those in need of auxiliary medication. Hepatic involvement appears to be related to the prognosis of the disease. In our study, bone marrow aspiration (BMA) and positive direct antiglobulin test (DAT) were observed in 66.67% and more than 90% of the patients, respectively. Children with VL in northwestern Iran responded well to glucantime. In case of resistance, amphotericin B was a good alternative. Early diagnosis is essential in reducing mortality rate. Wolters Kluwer Health 2016-11-04 /pmc/articles/PMC5591139/ /pubmed/27858891 http://dx.doi.org/10.1097/MD.0000000000005261 Text en Copyright © 2016 the Author(s). Published by Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. http://creativecommons.org/licenses/by-nc-sa/4.0
spellingShingle 4900
Abdinia, Babak
Oliaei-Motlagh, Mohammad
Teimouri-Dereshki, Amir
Pediatric visceral leishmaniasis in northwest of Iran
title Pediatric visceral leishmaniasis in northwest of Iran
title_full Pediatric visceral leishmaniasis in northwest of Iran
title_fullStr Pediatric visceral leishmaniasis in northwest of Iran
title_full_unstemmed Pediatric visceral leishmaniasis in northwest of Iran
title_short Pediatric visceral leishmaniasis in northwest of Iran
title_sort pediatric visceral leishmaniasis in northwest of iran
topic 4900
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591139/
https://www.ncbi.nlm.nih.gov/pubmed/27858891
http://dx.doi.org/10.1097/MD.0000000000005261
work_keys_str_mv AT abdiniababak pediatricvisceralleishmaniasisinnorthwestofiran
AT oliaeimotlaghmohammad pediatricvisceralleishmaniasisinnorthwestofiran
AT teimouridereshkiamir pediatricvisceralleishmaniasisinnorthwestofiran